• Announced Nasal Nalmefene program with positive Phase 1 data for OPNT003, a long-acting opioid antagonist for opioid overdose
  • Expanded into Acute Cannabinoid Overdose through an exclusive global licensing agreement with Sanofi for OPNT004 (drinabant)